Ethics Committee extends review of New York congressman

Associated Press |

WASHINGTON (AP) — The House Ethics Committee says it's extending its review of a congressman whose stock market trades prompted an advocacy group to request an investigation for possible violation of insider trading or conflict of interest laws.

Republican Rep. Chris Collins of New York was the largest shareholder of Australia's Innate Immunotherapeutics and was on the company's board of directors.

Advocacy groups say Collins sponsored legislation that could potentially benefit the company.

As part of its extension, the House Ethics Committee has released the findings of the independent Office of Congressional Ethics.

That office says there was substantial reason to believe Collins shared material, nonpublic information in the purchase on Innate stock. It's recommending dismissal of the allegation Collins purchased discounted stock unavailable to the public.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Lexaria Bioscience Corp

Lexaria Bioscience Corp is a food sciences company. It has two distinct consumer product brands: ViPova and Lexaria Energy. It uses patent pending technology to infuse hemp oil ingredients within…